The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Amanj Baker; Li-Chia Chen; Rachel A. Elliott; Brian Godman

doi:10.1186/s12913-015-1013-y

The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Amanj Baker, Li-Chia Chen, Rachel A. Elliott, Brian Godman

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

92 Downloads (Pure)

Abstract

In April/2009, the UK National Health Service initiated four Better Care Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of cheaper angiotensin-converting enzyme inhibitors (ACEIs) instead of expensive angiotensin receptor blockers (ARBs), with 80 % ACEIs/20 % ARBs as a proposed, and achievable target. The policy was intended to save costs without affecting patient outcomes. However, little is known about the actual impact of the BCBV indicator on ACEIs/ARBs utilisation and cost-savings. Therefore, this study aimed to evaluate the impact of BCBV policy on ACEIs/ARBs utilisation and cost-savings, including exploration of regional variations of the policy’s impact.

Original language	English
Article number	367
Number of pages	15
Journal	BMC Health Services Research
Volume	15
DOIs	https://doi.org/10.1186/s12913-015-1013-y
Publication status	Published - 10 Sept 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

better care better value
angiotensin-converting enzyme inhibitors
angiotensin receptor blockers
cardiovascular disease
hypertension
pharmacoeconomics

Access to Document

10.1186/s12913-015-1013-y

Baker-etal-BMCHSR-2015-The-impact-of-the-better-care-better-value-prescribing-policy-on-the-utilisation-of-angiotensin-converting-enzyme-inhibitorsFinal published version, 645 KBLicence: CC BY 4.0

Fingerprint

Dive into the research topics of 'The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design'. Together they form a unique fingerprint.

Data for "The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design"
Baker, A. (Contributor), Chen, L.-C. (Contributor), Elliott, R. A. (Creator) & Godman, B. (Creator), figshare, 21 Jun 2023
DOI: 10.6084/m9.figshare.c.3639290.v1
Dataset

Cite this

Baker, A., Chen, L.-C., Elliott, R. A., & Godman, B. (2015). The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design. BMC Health Services Research , 15, Article 367. https://doi.org/10.1186/s12913-015-1013-y

Baker, Amanj ; Chen, Li-Chia ; Elliott, Rachel A. et al. / The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design. In: BMC Health Services Research . 2015 ; Vol. 15.

@article{6d9ce576b411470b88c2e69e83b31032,

title = "The impact of the {\textquoteleft}Better Care Better Value{\textquoteright} prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design",

abstract = "In April/2009, the UK National Health Service initiated four Better Care Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of cheaper angiotensin-converting enzyme inhibitors (ACEIs) instead of expensive angiotensin receptor blockers (ARBs), with 80 \% ACEIs/20 \% ARBs as a proposed, and achievable target. The policy was intended to save costs without affecting patient outcomes. However, little is known about the actual impact of the BCBV indicator on ACEIs/ARBs utilisation and cost-savings. Therefore, this study aimed to evaluate the impact of BCBV policy on ACEIs/ARBs utilisation and cost-savings, including exploration of regional variations of the policy{\textquoteright}s impact.",

keywords = "better care better value, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, cardiovascular disease, hypertension, pharmacoeconomics",

author = "Amanj Baker and Li-Chia Chen and Elliott, \{Rachel A.\} and Brian Godman",

year = "2015",

month = sep,

day = "10",

doi = "10.1186/s12913-015-1013-y",

language = "English",

volume = "15",

journal = "BMC Health Services Research ",

issn = "1472-6963",

publisher = "BioMed Central",

}

Baker, A, Chen, L-C, Elliott, RA & Godman, B 2015, 'The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design', BMC Health Services Research , vol. 15, 367. https://doi.org/10.1186/s12913-015-1013-y

The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design. / Baker, Amanj; Chen, Li-Chia; Elliott, Rachel A. et al.
In: BMC Health Services Research , Vol. 15, 367, 10.09.2015.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

AU - Baker, Amanj

AU - Chen, Li-Chia

AU - Elliott, Rachel A.

AU - Godman, Brian

PY - 2015/9/10

Y1 - 2015/9/10

N2 - In April/2009, the UK National Health Service initiated four Better Care Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of cheaper angiotensin-converting enzyme inhibitors (ACEIs) instead of expensive angiotensin receptor blockers (ARBs), with 80 % ACEIs/20 % ARBs as a proposed, and achievable target. The policy was intended to save costs without affecting patient outcomes. However, little is known about the actual impact of the BCBV indicator on ACEIs/ARBs utilisation and cost-savings. Therefore, this study aimed to evaluate the impact of BCBV policy on ACEIs/ARBs utilisation and cost-savings, including exploration of regional variations of the policy’s impact.

AB - In April/2009, the UK National Health Service initiated four Better Care Better Value (BCBV) prescribing indicators, one of which encouraged the prescribing of cheaper angiotensin-converting enzyme inhibitors (ACEIs) instead of expensive angiotensin receptor blockers (ARBs), with 80 % ACEIs/20 % ARBs as a proposed, and achievable target. The policy was intended to save costs without affecting patient outcomes. However, little is known about the actual impact of the BCBV indicator on ACEIs/ARBs utilisation and cost-savings. Therefore, this study aimed to evaluate the impact of BCBV policy on ACEIs/ARBs utilisation and cost-savings, including exploration of regional variations of the policy’s impact.

KW - better care better value

KW - angiotensin-converting enzyme inhibitors

KW - angiotensin receptor blockers

KW - cardiovascular disease

KW - hypertension

KW - pharmacoeconomics

UR - http://www.biomedcentral.com/1472-6963/15/367/abstract

U2 - 10.1186/s12913-015-1013-y

DO - 10.1186/s12913-015-1013-y

M3 - Article

SN - 1472-6963

VL - 15

JO - BMC Health Services Research

JF - BMC Health Services Research

M1 - 367

ER -

Baker A, Chen LC, Elliott RA, Godman B. The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design. BMC Health Services Research . 2015 Sept 10;15:367. doi: 10.1186/s12913-015-1013-y

The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Datasets

Data for "The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design"

Cite this